
NASDAQHealthcareBiotechnology
Latest quote
$13.35
−$0.37 · -2.70%
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the advancement and commercialization of Haduvio, a potential treatment for debilitating neurologically mediated conditions. This orally administered, extended-release formulation of nalbuphine is currently undergoing Phase IIb/III clinical trials for chronic pruritus (severe itching) and persistent cough experienced by patients with idiopathic pulmonary fibrosis. Trevi Therapeutics also possesses a licensing agreement with Endo Pharmaceuticals Inc., granting it the rights to develop and market products containing nalbuphine hydrochloride in various formulations. Established in 2011, the company maintains its corporate headquarters in New Haven, Connecticut.
Previous close
$13.35
−$0.37 · -2.70%
Regular session · ET · Market data may be delayed.
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the advancement and commercialization of Haduvio, a potential treatment for debilitating neurologically mediated conditions. This orally administered, extended-release formulation of nalbuphine is currently undergoing Phase IIb/III clinical trials for chronic pruritus (severe itching) and persistent cough experienced by patients with idiopathic pulmonary fibrosis. Trevi Therapeutics also possesses a licensing agreement with Endo Pharmaceuticals Inc., granting it the rights to develop and market products containing nalbuphine hydrochloride in various formulations. Established in 2011, the company maintains its corporate headquarters in New Haven, Connecticut.
Day range
Current $13.35
52-week range
Current $13.35
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
40
Expensive
Sentiment
57
Mixed
Risk
45
Elevated Risk
Momentum
71
Gaining
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the advancement and commercialization of Haduvio, a potential treatment for debilitating neurologically mediated conditions. This orally administered, extended-release formulation of nalbuphine is currently undergoing Phase IIb/III clinical trials for chronic pruritus (severe itching) and persistent cough experienced by patients with idiopathic pulmonary fibrosis. Trevi Therapeutics also possesses a licensing agreement with Endo Pharmaceuticals Inc., granting it the rights to develop and market products containing nalbuphine hydrochloride in various formulations. Established in 2011, the company maintains its corporate headquarters in New Haven, Connecticut.
Day range
Current $13.35
52-week range
Current $13.35
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Research and development | 33.48M USD | 39.38M USD | 23.68M USD | 19.83M USD | 22.98M USD |
| Selling, general, and administrative | 15.85M USD | 12.15M USD | 10.24M USD | 10.07M USD | 9.49M USD |
| Operating expenses | 49.33M USD | 51.52M USD | 33.92M USD | 29.91M USD | 32.48M USD |
| Interest income | 6.54M USD | 3.6M USD | 4.75M USD | 1.74M USD | 10K USD |
| Interest expense | — | 4K USD | 391K USD | 780K USD | 1.2M USD |
| Depreciation and amortization | 144K USD | 147K USD | 123K USD | 43K USD | 50K USD |
| Operating income | −49.33M USD | −51.52M USD | −33.92M USD | −29.91M USD | −32.48M USD |
| Net income | −42.76M USD | −47.91M USD | −29.07M USD | −29.15M USD | −33.94M USD |
Company facts updated Nov 22, 2026.
Third-party consensus; not a GoAI recommendation.
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI50.12M0.00%689.3B USD0.03%$340.02-3.52%
iShares Russell 2000 ETFIWM39.01M0.05%71.54B USD0.19%$256.61-2.88%
Vanguard Extended Market ETFVXF18.51M0.02%30.2B USD0.05%$211.44-3.21%
iShares Russell 2000 Growth ETFIWO14.14M0.11%12.73B USD0.24%$320.43-3.57%
iShares Biotechnology ETFIBB9.97M0.10%10.53B USD0.44%$199.54-2.05%
State Street SPDR S&P Pharmaceuticals ETFXPH8.88M1.77%501.19M USD0.35%$62.15-2.00%
Vanguard Russell 2000 ETFVTWO8.67M0.05%16.8B USD0.06%$103.76-2.76%
Schwab U.S. Small-Cap ETFSCHA8.5M0.04%20.45B USD0.03%$30.51-2.83%
Vanguard Morningstar Total Stock Market ETFVTI
iShares Russell 2000 ETFIWM
Vanguard Extended Market ETFVXF
iShares Russell 2000 Growth ETFIWO
iShares Biotechnology ETFIBB
State Street SPDR S&P Pharmaceuticals ETFXPH
Vanguard Russell 2000 ETFVTWO
Schwab U.S. Small-Cap ETFSCHAAI-generated and delayed market data for informational and educational purposes only. Not investment advice.